SCHEMBL4450273

SCHEMBL4450273

C1CC[C@H]2NCC[C@H]2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30511 1.00
SCHEMBL9279532 1.00
SCHEMBL1254524 1.00
SCHEMBL4452609 1.00
SCHEMBL245244 1.00
SCHEMBL17681496 1.00
SCHEMBL9047529 1.00
SCHEMBL24870211 0.97 MBTD1 (0.39)
SCHEMBL2378409 0.97 MBTD1 (0.39)
Lithium SCHEMBL29834968 0.97 MBTD1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116615227-A Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof 费尔丹生物公司 2023-08-18 CN claimed
US-20090023661-A1 Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2009-01-22 US claimed
EP-1594520-A2 USE OF BRADYKININ-B2 RECEPTOR ANTAGONISTS FOR TREATING OSTEOARTHROSIS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-16 EP claimed
US-20040248809-A1 Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-12-09 US claimed
WO-2004069266-A2 USE OF BRADYKININ-B2 RECEPTOR ANTAGONISTS FOR TREATING OSTEOARTHROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-19 WO claimed
EP-0370453-B1 Peptides having a Brady kinine-inhibiting activity HOECHST AG (DE) 1994-06-15 EP claimed
EP-0370453-A2 Peptides having a Brady kinine-inhibiting activity HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-30 EP claimed
CN-116615227-A Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof 费尔丹生物公司 2023-08-18 CN disclosed
US-10017441-B2 Direct anti-markovnikov addition of acids to alkenes THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2018-07-10 US disclosed
US-9556230-B2 TFPI inhibitors and methods of use Baxalta GmbH (CH) 2017-01-31 US disclosed
US-20150232514-A1 TFPI INHIBITORS AND METHODS OF USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-08-20 US disclosed
US-9062057-B2 CCR5 antagonists for treating HIV PURDUE RESEARCH FOUNDATION (US) 2015-06-23 US disclosed
US-20140221420-A1 CCR5 ANTAGONISTS FOR TREATING HIV PURDUE RESEARCH FOUNDATION (US) 2014-08-07 US disclosed
EP-0370453-B1 Peptides having a Brady kinine-inhibiting activity HOECHST AG (DE) 1994-06-15 EP disclosed
EP-0370453-A2 Peptides having a Brady kinine-inhibiting activity HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-30 EP disclosed
US-4691022-A Process for the preparation of monocyclic, bicyclic and tricyclic aminoacids HOECHST AKTIENGESELLSCHAFT (DE) 1987-09-01 US disclosed
US-4624962-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1986-11-25 US disclosed
US-4515803-A HYPOTENSIVES Hoechst Aktiengesellschafat (DE) 1985-05-07 US disclosed
EP-0132580-A1 Process for the preparation of mono, bi and tricyclic aminoacids HOECHST AKTIENGESELLSCHAFT (DE) 1985-02-13 EP disclosed
EP-0074070-A1 Derivatives of urea, process for the preparation thereof, remedies containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1983-03-16 EP disclosed